SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the results of preclinical studies supporting the clinical evaluation of its investigational mTOR inhibitor, deforolimus, in combination with various anti-cancer agents that are used to treat sarcomas and endometrial cancer, as well as other cancers. These findings, which are being presented at the annual meeting of American Association for Cancer Research (AACR), provide further evidence of mTOR as a validated cancer target with broad potential clinical applicability.
